京新药业：盐酸卡利拉嗪已经提交了上市申请

Core Viewpoint - The company has submitted a listing application for its new drug, hydrochloride cariprazine, and is preparing for its commercialization in the domestic market [1] Group 1 - The company is the only manufacturer and seller of hydrochloride cariprazine in the market for at least the next 3 to 5 years [1] - The existing sales team has experience in selling drugs in the mental and neurological fields, which is expected to facilitate the commercialization of hydrochloride cariprazine [1] - The company aims to achieve good sales performance for hydrochloride cariprazine following its market entry [1]